PMID- 15991917
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20050714
LR  - 20190917
IS  - 1744-7658 (Electronic)
IS  - 1354-3784 (Linking)
VI  - 7
IP  - 1
DP  - 1998 Jan
TI  - Drug therapy for ocular allergy.
PG  - 27-55
AB  - The spectrum of ocular allergy ranges from mild, non-sight threatening disease, 
      such as hay fever, to disorders such as atopic keratoconjunctivitis (AKC) which 
      cause permanent ocular surface changes and reduced vision. The ideal treatment is 
      with topical preparations. Launched topical preparations include anti-histamines 
      and mast cell (MC) stabilisers, which are safe, but only moderately potent, 
      steroids, which are very potent, but carry very serious side-effects, and 
      cyclosporin A, which is not widely available and difficult to tolerate. There are 
      a number of anti-histamines, MC stabilisers (and combinations thereof) and 
      steroids in development which are of potential interest. Other possibilities for 
      therapeutic intervention include inhibition of tryptase, cyclooxygenase (COX), 
      leukotrienes (LTs), bradykinins (BKs), platelet activating factor (PAF) and 
      immunoglobulin E (IgE). Therapies based on cytokine antagonism and agonism, 
      T-cell inhibition and adhesion molecule antagonism might be expected to provide 
      safe, but potent new modes of treatment. The increasing interest in research into 
      the pathogenesis of ocular allergic inflammation may lead to more relevant 
      approaches, such as eosinophil inhibition. Success will be highly dependent on 
      the ability to produce suitable topical ophthalmic preparations.
FAU - Hingorani, M
AU  - Hingorani M
AD  - Moorfields Eye Hospital, City Road, London, UK.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Expert Opin Investig Drugs
JT  - Expert opinion on investigational drugs
JID - 9434197
EDAT- 2005/07/05 09:00
MHDA- 2005/07/05 09:01
CRDT- 2005/07/05 09:00
PHST- 2005/07/05 09:00 [pubmed]
PHST- 2005/07/05 09:01 [medline]
PHST- 2005/07/05 09:00 [entrez]
AID - 10.1517/13543784.7.1.27 [doi]
PST - ppublish
SO  - Expert Opin Investig Drugs. 1998 Jan;7(1):27-55. doi: 10.1517/13543784.7.1.27.